LIVIVO - Search results -

Search results

Result 1 - 10 of total 380

Search options

Article ; Online: Therapiesicherheit bei Verwendung nicht Vitamin-K-abhängiger oraler Antikoagulanzien bei Patienten mit Vorhofflimmern.

Hohnloser, S H

2016 Volume 41, Issue 1, Page(s) 37–47

Abstract: Non-vitamin K oral anticoagulants (NOAC) have now become established for stroke prevention in atrial fibrillation. The efficacy is at least as good if not better than that of vitamin K antagonists (VKA). The risk for major bleeding is less for NOAC than ... ...

Title translation	Treatment safety of non-vitamin K oral anticoagulants in patients with atrial fibrillation.
Abstract	Non-vitamin K oral anticoagulants (NOAC) have now become established for stroke prevention in atrial fibrillation. The efficacy is at least as good if not better than that of vitamin K antagonists (VKA). The risk for major bleeding is less for NOAC than for VKA, with a particular superiority concerning the avoidance of intracerebral hemorrhage. The outcome after major bleeding is more favorable in patients receiving NOAC compared to those treated with VKA. Specific reversal agents for NOAC are currently being tested which neutralize the effects of NOAC within minutes and the clinical introduction of the first one for the thrombin inhibitor dabigatran is imminent. Such specific antidotes will further improve the safety profile of NAOC.
MeSH term(s)	Administration, Oral ; Anticoagulants/administration & dosage ; Atrial Fibrillation/complications ; Atrial Fibrillation/drug therapy ; Evidence-Based Medicine ; Hemorrhage/chemically induced ; Hemorrhage/prevention & control ; Humans ; Risk Factors ; Stroke/etiology ; Stroke/prevention & control ; Treatment Outcome ; Vitamin K/administration & dosage
Chemical Substances	Anticoagulants ; Vitamin K (12001-79-5)
Language	German
Publishing date	2016-02
Publishing country	Germany
Document type	Journal Article
ZDB-ID	8262-4
ISSN	1615-6692 ; 0340-9937 ; 0946-1299
ISSN (online)	1615-6692
ISSN	0340-9937 ; 0946-1299
DOI	10.1007/s00059-015-4383-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1270: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 426: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Effect of dronedarone vs. placebo on atrial fibrillation progression: a post hoc analysis from ATHENA trial.

Blomström-Lundqvist, Carina / Naccarelli, Gerald V / McKindley, David S / Bigot, Gregory / Wieloch, Mattias / Hohnloser, Stefan H

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology

2023 Volume 25, Issue 3, Page(s) 845–854

Abstract: Aims: This post hoc analysis of the ATHENA trial (NCT00174785) assessed the effect of dronedarone on the estimated burden of atrial fibrillation (AF)/atrial flutter (AFL) progression to presumed permanent AF/AFL, and regression to sinus rhythm (SR), ... ...

Abstract	Aims: This post hoc analysis of the ATHENA trial (NCT00174785) assessed the effect of dronedarone on the estimated burden of atrial fibrillation (AF)/atrial flutter (AFL) progression to presumed permanent AF/AFL, and regression to sinus rhythm (SR), compared with placebo. Methods and results: The burden of AF/AFL was estimated by a modified Rosendaal method using available electrocardiograms (ECG). Cumulative incidence of permanent AF/AFL (defined as ≥6 months of AF/AFL until end of study) or permanent SR (defined as ≥6 months of SR until end of study) were calculated using Kaplan-Meier estimates. A log-rank test was used to assess statistical significance. Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were estimated using a Cox model, adjusted for treatment group. Of the 4439 patients included in this analysis, 2208 received dronedarone, and 2231 placebo. Baseline and clinical characteristics were well balanced between groups. Overall, 304 (13.8%) dronedarone-treated patients progressed to permanent AF/AFL compared with 455 (20.4%) treated with placebo (P < 0.0001). Compared with those receiving placebo, patients receiving dronedarone had a lower cumulative incidence of permanent AF/AFL (log-rank P < 0.001; HR: 0.65; 95% CI: 0.56-0.75), a higher cumulative incidence of permanent SR (log-rank P < 0.001; HR: 1.19; 95% CI: 1.09-1.29), and a lower estimated AF/AFL burden over time (P < 0.01 from Day 14 to Month 21). Conclusion: These results suggest that dronedarone could be a useful antiarrhythmic drug for early rhythm control due to less AF/AFL progression and more regression to SR vs. placebo, potentially reflecting reverse remodeling. Clinical trial registration: NCT00174785.
MeSH term(s)	Humans ; Amiodarone/adverse effects ; Anti-Arrhythmia Agents/adverse effects ; Atrial Fibrillation/diagnosis ; Atrial Fibrillation/drug therapy ; Atrial Fibrillation/epidemiology ; Atrial Flutter/diagnosis ; Atrial Flutter/drug therapy ; Atrial Flutter/epidemiology ; Dronedarone/adverse effects ; Hospitalization
Chemical Substances	Amiodarone (N3RQ532IUT) ; Anti-Arrhythmia Agents ; Dronedarone (JQZ1L091Y2)
Language	English
Publishing date	2023-02-08
Publishing country	England
Document type	Clinical Trial ; Journal Article
ZDB-ID	1449879-0
ISSN	1532-2092 ; 1099-5129
ISSN (online)	1532-2092
ISSN	1099-5129
DOI	10.1093/europace/euad023
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5434: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Anticoagulation in atrial fibrillation : Current evidence and guideline recommendations.

Erath, J W / Hohnloser, S H

Herz

2017 Volume 43, Issue 1, Page(s) 2–10

Abstract: Atrial fibrillation (AF) is the most frequently encountered sustained arrhythmia with a prevalence of 0.5-10%, depending predominantly on age. The arrhythmia is associated with significant morbidity and mortality, mainly due to thromboembolic events ... ...

Title translation	Antikoagulation bei Vorhofflimmern : Aktuelle Evidenz und Leitlinienempfehlungen.
Abstract	Atrial fibrillation (AF) is the most frequently encountered sustained arrhythmia with a prevalence of 0.5-10%, depending predominantly on age. The arrhythmia is associated with significant morbidity and mortality, mainly due to thromboembolic events including stroke and systemic embolisms. These complications can be effectively prevented with anticoagulation therapy either with vitamin K antagonists (VKA) or with non-vitamin K antagonists (NOAC). VKA therapy is effective in preventing strokes but these medications are difficult to use, are associated with significant bleeding risk, and have pharmacokinetic/dynamic properties that make their use cumbersome. NOACs-either factor II or factor Xa inhibitors-have been developed over the past two decades and have been tested against VKA in large randomized controlled trials. This trial evidence was complemented more recently by increasing real-world data comprising several 100,000 patients. Finally, NOACs have been examined for their use in specific clinical situations, for example, in patients undergoing cardioversion, catheter ablation, or coronary interventions. In all of these clinical scenarios, NOACs have been similarly effective or-in many instances-even superior to treatment with VKA. Recent guidelines, therefore, recommend NOAC therapy for stroke prevention in AF as first-line therapy.
MeSH term(s)	Anticoagulants/adverse effects ; Anticoagulants/therapeutic use ; Atrial Fibrillation/drug therapy ; Coronary Disease/therapy ; Drug Therapy, Combination ; Factor Xa Inhibitors/adverse effects ; Factor Xa Inhibitors/therapeutic use ; Humans ; Platelet Aggregation Inhibitors/adverse effects ; Platelet Aggregation Inhibitors/therapeutic use ; Prothrombin/antagonists & inhibitors ; Pulmonary Embolism/drug therapy ; Randomized Controlled Trials as Topic ; Risk Factors ; Stents ; Thromboembolism/prevention & control ; Venous Thrombosis/drug therapy ; Vitamin K/antagonists & inhibitors
Chemical Substances	Anticoagulants ; Factor Xa Inhibitors ; Platelet Aggregation Inhibitors ; Vitamin K (12001-79-5) ; Prothrombin (9001-26-7)
Language	English
Publishing date	2017-11-13
Publishing country	Germany
Document type	Journal Article ; Review
ZDB-ID	8262-4
ISSN	1615-6692 ; 0340-9937 ; 0946-1299
ISSN (online)	1615-6692
ISSN	0340-9937 ; 0946-1299
DOI	10.1007/s00059-017-4648-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1270: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 426: Show issues

Order via subito

Details ▾

Article ; Online: Inhibition of the K

Holst, Anders G / Tomcsányi, János / Vestbjerg, Birgitte / Grunnet, Morten / Sørensen, Ulrik S / Diness, Jonas G / Bentzen, Bo H / Edvardsson, Nils / Hohnloser, Stefan H / Bhatt, Deepak L / Dorian, Paul

Nature medicine

2023 Volume 30, Issue 1, Page(s) 106–111

Abstract: Existing antiarrhythmic drugs to treat atrial fibrillation (AF) have incomplete efficacy, contraindications and adverse effects, including proarrhythmia. AP30663, an inhibitor of the ... ...

Abstract	Existing antiarrhythmic drugs to treat atrial fibrillation (AF) have incomplete efficacy, contraindications and adverse effects, including proarrhythmia. AP30663, an inhibitor of the K
MeSH term(s)	Humans ; Atrial Fibrillation/drug therapy ; Bayes Theorem ; Treatment Outcome ; Anti-Arrhythmia Agents/adverse effects ; Infusions, Intravenous
Chemical Substances	Anti-Arrhythmia Agents
Language	English
Publishing date	2023-12-13
Publishing country	United States
Document type	Randomized Controlled Trial ; Clinical Trial, Phase II ; Journal Article
ZDB-ID	1220066-9
ISSN	1546-170X ; 1078-8956
ISSN (online)	1546-170X
ISSN	1078-8956
DOI	10.1038/s41591-023-02679-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4212: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 39: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Management von intrazerebralen Blutungen unter oraler Antikoagulation.

Sembill, J A / Kuramatsu, J B / Hohnloser, S H / Huttner, H B

Herz

2019 Volume 44, Issue 4, Page(s) 315–323

Abstract: The incidence of intracerebral hemorrhage (ICH) in patients using oral anticoagulation (OAC) will continue to increase with the demographic change of an aging population. As compared to primary spontaneous ICH, OAC-ICH is characterized by larger hematoma ...

Title translation	Management of oral anticoagulation related intracerebral hemorrhage.
Abstract	The incidence of intracerebral hemorrhage (ICH) in patients using oral anticoagulation (OAC) will continue to increase with the demographic change of an aging population. As compared to primary spontaneous ICH, OAC-ICH is characterized by larger hematoma volumes, more frequent hematoma enlargement and intraventricular hemorrhage resulting in an even worse prognosis. Specific treatment should focus on immediate reversal of anticoagulation in addition to the basic acute management of ICH. In ICH patients using vitamin K antagonists (VKA), complete anticoagulant reversal with an international normalized ratio (INR) <1.3 should be achieved as quickly as possible using prothrombin complex concentrate (PCC) with additional substitution of vitamin K. Patients with ICH under dabigatran treatment should receive idarucizumab. In ICH patients using factor-Xa inhibitors, andexanet should be administered as soon as approved in Europe or within clinical studies and if unavailable alternatively high-dose PCC administration. Regarding OAC resumption, results from randomized trials are pending. In comprehensive observational studies and meta-analyses ICH patients resuming OAC showed a reduced incidence of thromboembolic events and mortality without significantly increased rates of hemorrhagic complications. Non-vitamin K dependent oral anticoagulants (NOAC) might further increase the safety of OAC resumption, which should be initiated after 4-8 weeks for patients with atrial fibrillation. In contrast, VKA resumption in patients with mechanical heart valves should not take place earlier than 1 week after ICH. Generally, safety of OAC resumption appears to be affected by ICH localization along with the presence of cerebral microbleeding, cortical superficial siderosis and cortical/convexity subarachnoid hemorrhage, making it crucial to weigh up the individual patient risk with respect to thromboembolic versus hemorrhagic events.
MeSH term(s)	Administration, Oral ; Aged ; Anticoagulants/adverse effects ; Atrial Fibrillation/drug therapy ; Cerebral Hemorrhage/chemically induced ; Europe ; Humans ; Randomized Controlled Trials as Topic ; Vitamin K
Chemical Substances	Anticoagulants ; Vitamin K (12001-79-5)
Language	German
Publishing date	2019-04-02
Publishing country	Germany
Document type	Journal Article
ZDB-ID	8262-4
ISSN	1615-6692 ; 0340-9937 ; 0946-1299
ISSN (online)	1615-6692
ISSN	0340-9937 ; 0946-1299
DOI	10.1007/s00059-019-4802-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1270: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 426: Show issues

Order via subito

Details ▾

Article: Clinical outcomes of subcutaneous vs. transvenous implantable defibrillator therapy in a polymorbid patient cohort.

Kattih, Badder / Operhalski, Felix / Boeckling, Felicitas / Hecker, Florian / Michael, Felix / Vamos, Mate / Hohnloser, Stefan H / Erath, Julia W

Frontiers in cardiovascular medicine

2022 Volume 9, Page(s) 1008311

Abstract: Background: The subcutaneous implantable cardioverter-defibrillator (S-ICD) has been designed ... Objective: The aim of this single-center study was to assess clinical outcomes of S-ICD and single-chamber ... patients who underwent either S-ICD (: Results: The median age of the study population was 66.0 years ...

Abstract	Background: The subcutaneous implantable cardioverter-defibrillator (S-ICD) has been designed to overcome lead-related complications and device endocarditis. Lacking the ability for pacing or resynchronization therapy its usage is limited to selected patients at risk for sudden cardiac death (SCD). Objective: The aim of this single-center study was to assess clinical outcomes of S-ICD and single-chamber transvenous (TV)-ICD in an all-comers population. Methods: The study cohort comprised a total of 119 ICD patients who underwent either S-ICD ( Results: The median age of the study population was 66.0 years, 22.7% of the patients were female. The underlying heart disease was ischemic cardiomyopathy (61.4%) with a median LVEF of 30%. Only 52.9% had received an ICD for primary prevention, most of the patients (67.3%) had advanced heart failure (NYHA class II-III) and 16.8% were in atrial fibrillation. CCI was 5 points in TV-ICD patients vs. 4 points for patients with S-ICD ( Conclusion: Clinical outcomes of the S-ICD and TV-ICD revealed no differences in the composite endpoint including survival, freedom of hospitalization and device-associated events, even after careful adjustment for potential confounders. Moreover, the CCI was evaluated in a S-ICD cohort demonstrating higher survival rates than predicted by the CCI in young, polymorbid (S-)ICD patients.
Language	English
Publishing date	2022-10-18
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2781496-8
ISSN	2297-055X
ISSN	2297-055X
DOI	10.3389/fcvm.2022.1008311
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Dabigatran for stroke prevention in atrial fibrillation.

Hohnloser, S H / Diener, H-C

Hamostaseologie

2012 Volume 32, Issue 3, Page(s) 216–220

Abstract: Dabigatran is a novel direct thrombin inhibitor that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation. In the pivotal RE-LY study, dabigatran 110 mg BID was ... ...

Abstract	Dabigatran is a novel direct thrombin inhibitor that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation. In the pivotal RE-LY study, dabigatran 110 mg BID was demonstrated to be associated with a stroke rate similar to that observed with warfarin (INR target 2.0 to 3.0), but with a lower rate of major haemorrhage. Dabigatran administered at a dose of 150 mg BID was significantly more effective in stroke prevention than warfarin and showed a similar rate of major hemorrhages. Of note, both dosages resulted in an approximately 60-70% relative risk reduction of haemorrhagic stroke. The dosage of 110 mg BID should be preferably used in patients aged 75-80 years or older as the rate of extracranial bleeding events tends to increase with dabigatran 150 mg BID above this age limit. In RE-LY, myocardial infarcts occurred at a very low incidence. There were numerically more myocardial infarcts in dabigatran-treated patients than in warfarin patients; however, other myocardial ischaemic events were similar in the three treatment arms.
MeSH term(s)	Antithrombins/administration & dosage ; Antithrombins/adverse effects ; Atrial Fibrillation/complications ; Atrial Fibrillation/drug therapy ; Benzimidazoles/administration & dosage ; Benzimidazoles/adverse effects ; Dabigatran ; Evidence-Based Medicine ; Humans ; Stroke/etiology ; Stroke/prevention & control ; Thrombosis/etiology ; Thrombosis/prevention & control ; Treatment Outcome ; beta-Alanine/administration & dosage ; beta-Alanine/adverse effects ; beta-Alanine/analogs & derivatives
Chemical Substances	Antithrombins ; Benzimidazoles ; beta-Alanine (11P2JDE17B) ; Dabigatran (I0VM4M70GC)
Keywords	covid19
Language	English
Publishing date	2012
Publishing country	Germany
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	801512-0
ISSN	0720-9355
ISSN	0720-9355
DOI	10.5482/ha-1196
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1631: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF.

Harrington, Josephine / Carnicelli, Anthony P / Hua, Kaiyuan / Wallentin, Lars / Patel, Manesh R / Hohnloser, Stefan H / Giugliano, Robert P / Fox, Keith A A / Hijazi, Ziad / Lopes, Renato D / Pokorney, Sean D / Hong, Hwanhee / Granger, Christopher B

Circulation

2023 Volume 147, Issue 23, Page(s) 1748–1757

Abstract: ... dose DOAC, lower-dose DOAC, and warfarin). Outcomes included stroke and systemic embolism (S/SE), major ... of S/SE, major bleeding, ICH, and death increased significantly with worsening kidney function. Across ... with a higher incidence of S/SE and death. These findings support the use of standard-dose DOACs over warfarin ...

Abstract	Background: There is uncertainty surrounding the use of direct oral anticoagulants (DOACs) in patients with kidney dysfunction. Methods: Using the COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) database (data from RE-LY [Randomized Evaluation of Long-term Anticoagulation Therapy], ROCKET AF [Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation], ARISTOTLE [Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation], and ENGAGE AF-TIMI 48 [Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48]), we performed an individual patient-level network meta-analysis to evaluate the safety and efficacy of DOACs versus warfarin across continuous creatinine clearance (CrCl). A multivariable Cox model including treatment-by-CrCl interaction with random effects was fitted to estimate hazard ratios for paired treatment strategies (standard-dose DOAC, lower-dose DOAC, and warfarin). Outcomes included stroke and systemic embolism (S/SE), major bleeding, intracranial hemorrhage (ICH), and death. Results: Among 71 683 patients (mean age, 70.6±9.4 years; 37.3% female; median follow-up, 23.1 months), the mean CrCl was 75.5±30.5 mL/min. The incidence of S/SE, major bleeding, ICH, and death increased significantly with worsening kidney function. Across continuous CrCl values down to 25 mL/min, the hazard of major bleeding did not change for patients randomized to standard-dose DOACs compared with those randomized to warfarin ( Conclusions: Standard-dose DOACs are safer and more effective than warfarin down to a CrCl of at least 25 mL/min. Lower-dose DOACs do not significantly lower the incidence of bleeding or ICH compared with standard-dose DOACs but are associated with a higher incidence of S/SE and death. These findings support the use of standard-dose DOACs over warfarin in patients with kidney dysfunction.
MeSH term(s)	Humans ; Female ; Middle Aged ; Aged ; Aged, 80 and over ; Male ; Warfarin/adverse effects ; Network Meta-Analysis ; Atrial Fibrillation/diagnosis ; Atrial Fibrillation/drug therapy ; Atrial Fibrillation/complications ; Factor Xa ; Anticoagulants/therapeutic use ; Stroke/epidemiology ; Hemorrhage/epidemiology ; Intracranial Hemorrhages/chemically induced ; Embolism/epidemiology ; Kidney ; Administration, Oral ; Randomized Controlled Trials as Topic
Chemical Substances	Warfarin (5Q7ZVV76EI) ; Factor Xa (EC 3.4.21.6) ; Anticoagulants
Language	English
Publishing date	2023-04-12
Publishing country	United States
Document type	Meta-Analysis ; Journal Article
ZDB-ID	80099-5
ISSN	1524-4539 ; 0009-7322 ; 0069-4193 ; 0065-8499
ISSN (online)	1524-4539
ISSN	0009-7322 ; 0069-4193 ; 0065-8499
DOI	10.1161/CIRCULATIONAHA.122.062752
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui IV Zs.60: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon in Geriatric and Non-Geriatric Patients with Non-Valvular Atrial Fibrillation.

Hohmann, Christopher / Hohnloser, Stefan H / Jacob, Josephine / Walker, Jochen / Baldus, Stephan / Pfister, Roman

Thrombosis and haemostasis

2019 Volume 119, Issue 6, Page(s) 971–980

Abstract: Geriatric characteristics such as high age, multi-morbidity, polypharmacy and frailty are common in patients with atrial fibrillation (AF). In a retrospective study using a German claims database, effectiveness (ischaemic stroke/systemic embolism) and ... ...

Abstract	Geriatric characteristics such as high age, multi-morbidity, polypharmacy and frailty are common in patients with atrial fibrillation (AF). In a retrospective study using a German claims database, effectiveness (ischaemic stroke/systemic embolism) and safety (intracerebral, gastrointestinal and major extracranial bleeding) were compared in patients with non-valvular AF starting non-vitamin K oral antagonists (NOACs) (apixaban, dabigatran and rivaroxaban) and phenprocoumon. Cox proportional hazards models were used to calculate adjusted hazard ratios, and interaction terms of the treatment group and geriatric status (defined by age ≥75 years, frailty, ≥ 4 co-morbidities and polypharmacy) were entered into the model. A total of 42,562 and 27,939 patients initiated NOAC and phenprocoumon treatment (mean age 74 years ± 11, 51% male) with a follow-up time of 147,785 person-years. Note that 52.9% of patients were elderly, 50.8% were frail, 37.0% were co-morbid and 46.5% had polypharmacy. NOAC use was not associated with effectiveness and gastrointestinal bleeding, neither in geriatric nor in non-geriatric patients. The hazard of major extracranial and intracranial bleeding was significantly decreased for NOAC use, with similar risk reduction in geriatric and non-geriatric patients: major extracranial bleeding 0.70 (95% confidence interval [CI], 0.56-0.87) to 0.73 (95% CI, 0.60-0.89) for the geriatric groups and 0.71 (95% CI, 0.56-0.93) to 0.76 (0.59-0.98) for the non-geriatric groups (
MeSH term(s)	Administration, Oral ; Aged ; Aged, 80 and over ; Anticoagulants/therapeutic use ; Atrial Fibrillation/drug therapy ; Dabigatran/therapeutic use ; Female ; Geriatrics ; Germany/epidemiology ; Humans ; Middle Aged ; Phenprocoumon/therapeutic use ; Proportional Hazards Models ; Pyrazoles/therapeutic use ; Pyridones/therapeutic use ; Retrospective Studies ; Rivaroxaban/therapeutic use ; Vitamin K/metabolism
Chemical Substances	Anticoagulants ; Pyrazoles ; Pyridones ; Vitamin K (12001-79-5) ; apixaban (3Z9Y7UWC1J) ; Rivaroxaban (9NDF7JZ4M3) ; Dabigatran (I0VM4M70GC) ; Phenprocoumon (Q08SIO485D)
Language	English
Publishing date	2019-03-21
Publishing country	Germany
Document type	Journal Article
ZDB-ID	518294-3
ISSN	2567-689X ; 0340-6245
ISSN (online)	2567-689X
ISSN	0340-6245
DOI	10.1055/s-0039-1683422
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.192: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 433: Show issues

Order via subito

Details ▾

Article ; Online: Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature.

Hohnloser, Stefan H / Camm, A John

2013 Volume 15, Issue 10, Page(s) 1407–1411

Abstract: ... 6.85, P = n.s.). The pooled rate of major bleeding events was similar for warfarin and ... for dabigatran (OR 1.05, 95% CI 0.62-1.80; P = n.s.). Rates of minor bleeding events were also similar between ...

Abstract	Aims: To summarize and analyse the published literature on the efficacy and safety of dabigatran for anticoagulation during atrial fibrillation (AF) ablation. Methods and results: A comprehensive search of the literature in the English language was conducted and 10 studies were identified which compared dabigatran therapy with warfarin. Data were extracted and meta-analysed using appropriate methodology. There was significant clinical heterogeneity among studies concerning study designs and methodologies. Most studies consisted of retrospective single-centre observational studies. A total of 3648 patients were included of whom 2241 were receiving warfarin and 1407 dabigatran. Only 12 thrombo-embolic events were reported, 3 during warfarin and 9 during dabigatran therapy [odds ratio (OR) 2.38, 95% confidence interval (CI) 0.82-6.85, P = n.s.). The pooled rate of major bleeding events was similar for warfarin and for dabigatran (OR 1.05, 95% CI 0.62-1.80; P = n.s.). Rates of minor bleeding events were also similar between the two treatment groups. Conclusion: Dabigatran has similar efficacy and safety compared with warfarin when used for periprocedural anticoagulation during AF ablation.
MeSH term(s)	Administration, Oral ; Anticoagulants/administration & dosage ; Anticoagulants/adverse effects ; Anticoagulants/therapeutic use ; Atrial Fibrillation/complications ; Atrial Fibrillation/diagnosis ; Atrial Fibrillation/drug therapy ; Atrial Fibrillation/surgery ; Benzimidazoles/administration & dosage ; Benzimidazoles/adverse effects ; Benzimidazoles/therapeutic use ; Catheter Ablation/adverse effects ; Chi-Square Distribution ; Dabigatran ; Hemorrhage/chemically induced ; Humans ; Odds Ratio ; Pyridines/administration & dosage ; Pyridines/adverse effects ; Pyridines/therapeutic use ; Risk Factors ; Thromboembolism/etiology ; Thromboembolism/prevention & control ; Treatment Outcome ; Warfarin/therapeutic use
Chemical Substances	Anticoagulants ; Benzimidazoles ; Pyridines ; Warfarin (5Q7ZVV76EI) ; Dabigatran (I0VM4M70GC)
Language	English
Publishing date	2013-10
Publishing country	England
Document type	Journal Article ; Meta-Analysis ; Review
ZDB-ID	1449879-0
ISSN	1532-2092 ; 1099-5129
ISSN (online)	1532-2092
ISSN	1099-5129
DOI	10.1093/europace/eut241
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5434: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito